Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Non-Current Deffered Revenue (2020 - 2025)

Beam Therapeutics (BEAM) has disclosed Non-Current Deffered Revenue for 6 consecutive years, with $10.2 million as the latest value for Q3 2025.

  • Quarterly Non-Current Deffered Revenue fell 82.43% to $10.2 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $10.2 million through Sep 2025, down 82.43% year-over-year, with the annual reading at $33.2 million for FY2024, 69.77% down from the prior year.
  • Non-Current Deffered Revenue for Q3 2025 was $10.2 million at Beam Therapeutics, down from $20.3 million in the prior quarter.
  • The five-year high for Non-Current Deffered Revenue was $262.3 million in Q4 2021, with the low at $10.2 million in Q3 2025.
  • Average Non-Current Deffered Revenue over 5 years is $115.7 million, with a median of $104.7 million recorded in 2023.
  • The sharpest move saw Non-Current Deffered Revenue skyrocketed 66474.37% in 2021, then tumbled 82.43% in 2025.
  • Over 5 years, Non-Current Deffered Revenue stood at $262.3 million in 2021, then decreased by 22.92% to $202.2 million in 2022, then plummeted by 45.65% to $109.9 million in 2023, then tumbled by 69.77% to $33.2 million in 2024, then plummeted by 69.41% to $10.2 million in 2025.
  • According to Business Quant data, Non-Current Deffered Revenue over the past three periods came in at $10.2 million, $20.3 million, and $49.4 million for Q3 2025, Q2 2025, and Q1 2025 respectively.